Welcome to our dedicated page for Allstate SEC filings (Ticker: ALL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allstate’s 10-K can exceed 300 pages of loss triangles, catastrophe risk tables, and actuarial jargon—enough to overwhelm even seasoned analysts. If you are digging for Allstate insider trading Form 4 transactions before earnings or trying to trace reserve changes buried deep in footnotes, the search can feel endless.
Stock Titan solves that problem. Our AI reads every Allstate quarterly earnings report 10-Q filing, flags segment profitability swings, and delivers Allstate Form 4 insider transactions real-time to your dashboard. Get Allstate SEC filings explained simply; each note is paired with bite-sized context so you can move from raw document to Allstate earnings report filing analysis in minutes. Interactive filters help in understanding Allstate SEC documents with AI, highlighting where catastrophe losses hit income, how investment gains flow through results, and which geographies drive combined ratios.
Need governance details? Drill into the Allstate annual report 10-K simplified section for reserve adequacy discussions, open the Allstate proxy statement executive compensation snapshot to see incentive structures, or track risk disclosures through Allstate 8-K material events explained. Professional investors monitor Allstate executive stock transactions Form 4 alongside claim-severity trends; our platform puts both in one place, updated the moment EDGAR posts. Save hours, surface the metrics that move the stock, and make better decisions with AI-powered clarity.
Triumph Financial, Inc. (TFIN) – Form 4 insider filing
Director Laura Easley reported the July 1, 2025 receipt of 653 fully-vested common shares granted under the company’s 2014 Omnibus Incentive Plan. The award was recorded at $0 cost, indicating a standard equity compensation grant rather than an open-market purchase. Following the transaction, Easley’s direct holdings rose to 8,301 shares. She also reports 1,895 shares held indirectly as trustee of the Easley Family Trust, for total beneficial ownership of 10,196 shares.
No derivative securities were involved, and there were no dispositions. This filing reflects routine board-level compensation and represents a modest increase in insider ownership (approximately 0.04% of TFIN’s 25 million share count, assuming prior public float). While not financially material to the company, insider accumulation can be viewed as a modestly positive governance signal.
Form 4 overview: Director Laura Berner of Bolt Biotherapeutics (BOLT) reported a single equity-based transaction dated May 27 2025. She received a non-qualified stock option for 1,100 common shares at an exercise price of $6.40 per share. All figures give effect to the 1-for-20 reverse stock split that the company executed on June 6 2025.
Key terms of the grant:
- Vesting: Options vest on the earlier of May 27 2026 or the day immediately prior to the next annual meeting, subject to continued service.
- Change-in-control: The award vests in full upon a change-in-control event.
- Expiration: May 26 2035 (10-year life).
No shares were purchased or sold; the filing reflects compensation-related option issuance. Post-grant, Berner beneficially owns 1,100 derivative securities and no disclosed non-derivative common shares.
Corporate context: The recent reverse split consolidated each 20 common shares into one, reducing the share count and proportionally increasing exercise prices. Prior to the split, the grant was for 22,000 shares at $0.32 per share. The filing provides no additional financial or operational data.
Sezzle Inc. (ticker SEZL) has filed a Form 144 indicating the intention to sell 3,000 common shares through Fidelity Brokerage Services on or about 01 July 2025. The proposed sale is valued at approximately $528,240, representing less than 0.01 % of the 33.29 million shares outstanding. During the preceding three months, related parties—primarily Stacy Paradis and Paul V. Paradis—have already sold an aggregated 125,200 shares for roughly $9.7 million, suggesting an ongoing insider-selling program. Shares were originally acquired via restricted-stock vesting on 13 October 2016 and are being sold under Rule 144, which requires the filer to affirm no possession of undisclosed materially adverse information. While the filing is routine and the amount modest relative to float, continued insider sales may raise questions about executive confidence and could exert marginal selling pressure.
FAQ
What is the current stock price of Allstate (ALL)?
What is the market cap of Allstate (ALL)?
What is the core business of Allstate Corporation?
How does Allstate generate its revenue?
What makes Allstate's agent network unique?
How does Allstate manage risk within its operations?
In what ways does Allstate differentiate itself from competitors?
What are the primary insurance products offered by Allstate?
How does Allstate address the needs of its diverse clientele?
Why is Allstate considered a reliable name in property-casualty insurance?
